Eric Loumeau Sells 10,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock

by · The Markets Daily

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) insider Eric Loumeau sold 10,000 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $46.00, for a total transaction of $460,000.00. Following the transaction, the insider directly owned 9,088 shares of the company’s stock, valued at approximately $418,048. This represents a 52.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB traded up $1.84 during midday trading on Thursday, hitting $47.53. The company’s stock had a trading volume of 416,584 shares, compared to its average volume of 693,419. The stock’s 50 day simple moving average is $38.13 and its 200 day simple moving average is $28.60. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -16.85 and a beta of 0.29. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $48.44.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. As a group, analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has approved a share repurchase program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently made changes to their positions in ANAB. US Bancorp DE lifted its holdings in shares of AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 979 shares during the period. Larson Financial Group LLC raised its position in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. raised its position in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. boosted its holdings in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares in the last quarter.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several research reports. Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research report on Monday, November 24th. Wells Fargo & Company increased their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Barclays decreased their price target on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Finally, Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $55.40.

View Our Latest Report on AnaptysBio

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

See Also